NCT06980103 Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
| NCT ID | NCT06980103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Georgetown University |
| Condition | Thyroid Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 408 participants |
| Start Date | 2025-08-06 |
| Primary Completion | 2029-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 408 participants in total. It began in 2025-08-06 with a primary completion date of 2029-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later. Researchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 and older * Patients diagnosed with intermediate risk DTC \< 6 months ago and who are making a decision about RAI treatment * Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate. * Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study. Exclusion Criteria: * Diagnosis of low risk or high risk DTC * Prior history of RAI * Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)
Frequently Asked Questions
Who can join the NCT06980103 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06980103 currently recruiting?
Yes, NCT06980103 is actively recruiting participants. Visit ClinicalTrials.gov or contact Georgetown University to inquire about joining.
Where is the NCT06980103 trial being conducted?
This trial is being conducted at Washington D.C., United States, Washington D.C., United States, Falls Church, United States.
Who is sponsoring the NCT06980103 clinical trial?
NCT06980103 is sponsored by Georgetown University. The trial plans to enroll 408 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.